Prof. Huijuan Yang 杨慧娟
Chief Physician, Professor
Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of cervical, endometrial, ovarian, vulvar, and vaginal cancers, including robotic and laparoscopic procedures. Management of advanced or recurrent gynecologic malignancies with chemotherapy, targeted therapy, immunotherapy, and endocrine therapy. Prevention and monitoring of HPV-related diseases.
Dr. Yang earned a medical degree from Shanghai Medical University in 1994, a master’s in oncology in 1997, and a PhD in obstetrics and gynecology from the University of Hong Kong in 2004. Training included roles at Stanford University and Memorial Sloan Kettering Cancer Center. With over 20 years of experience, Dr. Yang serves as Deputy Director of the Department of Gynecologic Oncology at Fudan University Shanghai Cancer Center.
Professional roles
- Member, Gynecologic Oncology Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Ovarian Cancer Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Gynecologic Oncology Professional Committee, China Medical Education Association
- Member, Micro-invasive Medicine Professional Committee, Chinese Medical Doctor Association
Name order: in Chinese the family name comes first (Yang Huijuan). Papers usually list the name as Huijuan Yang or Yang H.
Selected publications
61 papers on PubMed matched by name and affiliation; 26 as first or senior author since 2016. Most recent first- or senior-author papers:
- Adv Sci (Weinh), 2026 (senior author): Integrative Multi-Omics Analysis Reveals a Mitochondrial-Immune Axis Associated With Neoadjuvant Chemotherapy Response in High-Grade Serous Ovarian Cancer. PubMed 42474029
- Hum Cell, 2025 (senior author): Establishment and comparison of three sublines from a human uterine carcinosarcoma cell line, ESCA. PubMed 40455147
- Br J Cancer, 2024 (senior author): Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers. PubMed 38253702
- Ann Med, 2023 (senior author): Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival. PubMed 37272300
- Immunology, 2023 (senior author): Targeting PI3Kα increases the efficacy of anti-PD-1 antibody in cervical cancer. PubMed 37469254
- Cancer Lett, 2023 (senior author): The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by promoting glutamine metabolism in cervical cancer. PubMed 36646410
- Br J Cancer, 2022 (senior author): Integrative genomic and transcriptomic analysis reveals immune subtypes and prognostic markers in ovarian clear cell carcinoma. PubMed 35043008
- BMC Cancer, 2022 (senior author): The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma. PubMed 35461222
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion